Literature DB >> 10595568

A 1997-1998 national surveillance study: Moraxella catarrhalis and Haemophilus influenzae antimicrobial resistance in 34 US institutions.

S S Richter1, A B Brueggemann, H K Huynh, P R Rhomberg, E M Wingert, R Flamm, G V Doern.   

Abstract

From November 1, 1997 to April 30, 1998, 726 Moraxella catarrhalis isolates and 1529 Haemophilus influenzae isolates were obtained from 34 medical centres throughout the United States. Rates of beta-lactamase production were 94.6% among M. catarrhalis and 31.1% among H. influenzae strains. Susceptibility rates of M. catarrhalis isolates to selected antimicrobial agents were greater than 99% for amoxycillin-clavulanate, cefixime, cefpodoxime, cefuroxime, cefaclor, loracarbef, clarithromycin, azithromycin, chloramphenicol and tetracycline, 97.8% for cefprozil, 50.4% for trimethoprim-sulphamethoxazole and 28.1% for ampicillin. Of the antimicrobials tested against H. influenzae, the only agents with susceptibility rates below 96% were loracarbef (87.6%), cefprozil (83.4%), cefaclor (82.7%), trimethoprim-sulphamethoxazole (67.3%) and ampicillin (64.7%). The clarithromycin susceptibility rate was 67.4% but this agent was not tested in the presence of its 14-OH metabolite.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10595568     DOI: 10.1016/s0924-8579(99)00112-0

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  9 in total

1.  Molecular characterization of the beta-lactamases from clinical isolates of Moraxella (Branhamella) catarrhalis obtained from 24 U.S. medical centers during 1994-1995 and 1997-1998.

Authors:  S S Richter; P L Winokur; A B Brueggemann; H K Huynh; P R Rhomberg; E M Wingert; G V Doern
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

2.  Genetic and molecular characterization of beta-lactamase-negative ampicillin-resistant Haemophilus influenzae with unusually high resistance to ampicillin.

Authors:  Frank S Kaczmarek; Thomas D Gootz; Fadia Dib-Hajj; Wenchi Shang; Shawn Hallowell; Melissa Cronan
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

3.  In vitro activity of ABT-773, a new ketolide, against recent clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.

Authors:  A B Brueggemann; G V Doern; H K Huynh; E M Wingert; P R Rhomberg
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

Review 4.  Cefuroxime axetil: an updated review of its use in the management of bacterial infections.

Authors:  L J Scott; D Ormrod; K L Goa
Journal:  Drugs       Date:  2001       Impact factor: 9.546

5.  Decreasing prevalence of beta-lactamase production among respiratory tract isolates of Haemophilus influenzae in the United States.

Authors:  Kris P Heilmann; Cassie L Rice; Ashley L Miller; Norma J Miller; Susan E Beekmann; Michael A Pfaller; Sandra S Richter; Gary V Doern
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

Review 6.  Amoxicillin/clavulanic acid: a review of its use in the management of paediatric patients with acute otitis media.

Authors:  Jane Easton; Stuart Noble; Caroline M Perry
Journal:  Drugs       Date:  2003       Impact factor: 9.546

7.  Rapidly increasing prevalence of beta-lactamase-nonproducing, ampicillin-resistant Haemophilus influenzae type b in patients with meningitis.

Authors:  Keiko Hasegawa; Naoko Chiba; Reiko Kobayashi; Somay Y Murayama; Satoshi Iwata; Keisuke Sunakawa; Kimiko Ubukata
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

Review 8.  The role of beta-lactamase-producing-bacteria in mixed infections.

Authors:  Itzhak Brook
Journal:  BMC Infect Dis       Date:  2009-12-14       Impact factor: 3.090

Review 9.  Acute bronchitis: state of the art diagnosis and therapy.

Authors:  Fernando J Martinez
Journal:  Compr Ther       Date:  2004
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.